Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 11: EUROPA-Studie - Blutdruck Abb. 12: Perindopril - Gewebs-ACE Abb. 13: Perindopril - Bradykinin Aktuelles Bild - Abb. 14: Perindopril - Endotheliale Dysfunktion Abb. 15: Perindopril - Endothliale Dysfunktion Abb. 16: Perindopril - Widerstandsarterien Abb. 17: Perindopril - Widerstandsarterien Zum letzten Bild
Abbildung 14: Perindopril - Endotheliale Dysfunktion
Perindopril corrects endothelial function as observed in this study, not accomplished by different antihypertensive therapies (ACEI, ARB, CCB and Beta-blockers) in essential hypertensive patients. Only perindopril managed to significantly increase flow mediated dilation after 6 months. AT1 receptor antagonist did not improve endothelial dysfunction leading to the conclusion that the beneficial effect of perindopril is related to bradykinin dependant mechanisms.
 
Perindopril - Endotheliale Dysfunktion
Vorheriges Bild Nächstes Bild   


Abbildung 14: Perindopril - Endotheliale Dysfunktion
Perindopril corrects endothelial function as observed in this study, not accomplished by different antihypertensive therapies (ACEI, ARB, CCB and Beta-blockers) in essential hypertensive patients. Only perindopril managed to significantly increase flow mediated dilation after 6 months. AT1 receptor antagonist did not improve endothelial dysfunction leading to the conclusion that the beneficial effect of perindopril is related to bradykinin dependant mechanisms.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung